Saitama Medical University International Medical Center Selects MRIdian MRI-Guided Radiation Therapy System
CLEVELAND, July 19, 2022 /PRNewswire/ — ViewRay, Inc. (NASDAQ: VRAY) today announced that Saitama Medical University International Medical Center has purchased an MRIdian MRI-guided radiation therapy system to complement its new comprehensive cancer center in Yamane, Hidaka-City. The MRIdian System Will Enable Saitama Medical University to Offer Advanced MRI-Guided Radiation Therapy Technology to Cancer Patients Seeking Personalized Treatment for Pancreatic, Prostate, Lung, Liver, Breast and Oligometastatic Cancers .
Saitama Medical University International Medical Center is expected to install its MRIdian system in December 2022, with first patient treatments beginning in early 2023. The center is eager to use real-time tracking and beam-triggering technology automated from MRIdian to support aggressive stereotactic body radiotherapy. (SBRT) and handle complex cases. Indications of particular interest to researchers at Saitama Medical University are the pancreas and prostate, with a desire to participate in international multicenter research hospital trials.
“Our focus on high quality medical treatment with a focus on safety and patient satisfaction makes MRIdian a perfect complement to our cancer treatment offerings,” said Dr. Shingo Kato, Professor and director of the radiation oncology department. “The ability to visualize and track the tumor and control the beam in real time under MRI guidance and tailor treatment delivery to the unique anatomical and tumor changes in each patient fully supports our patient-centered approach to care and will be of significant benefit to patients throughout the region.
Saitama Medical University International Medical Center was established in April 2007 with the aim of contributing to regional and Japanese medicine, with the aim of creating an internationally competitive world-class hospital. In February 2015, Saitama Medical University International Medical Center became the first teaching hospital in Japan to acquire Joint Commission International (JCI) certification, demonstrating its adherence to international quality standards for medical quality and safety. The motto of the Comprehensive Cancer Center is to treat cancer patients holistically, not to treat the tumor itself.
The MRIdian system provides oncologists with exceptional anatomical visualization through diagnostic-quality MRI images and the ability to tailor a radiation treatment plan to the targeted cancer with the patient on the table. This combination allows physicians to set narrow treatment margins to avoid unnecessary radiation exposure to vulnerable organs at risk and healthy tissues and allows the delivery of ablative radiation doses in five treatment sessions or less, without relying on implanted markers. By providing real-time, continuous tracking of the target and organs at risk, MRIdian enables automatic radiation beam triggering if the target moves outside of user-defined margins. This allows the prescribed dose to be delivered to the target, while sparing surrounding healthy tissue and critical structures, minimizing the toxicities typically associated with conventional radiation therapy.
Nearly 24,000 patients have been treated with IRMdian. Currently, 53 MRI systems are installed in hospitals around the world where they are used to treat a wide variety of solid tumors and are the subject of many ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations.
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® MRI-guided radiation therapy system. MRIdian is built on a proprietary high-definition MR imaging system designed from the ground up to meet the unique challenges and clinical workflow of advanced radiation oncology. Unlike MRI systems used in diagnostic radiology, MRIdian’s high-definition MRI has been specifically designed to address specific challenges including beam distortion, skin toxicity, and other issues that can arise when high magnetic fields interact with beams of radiation. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
SOURCE ViewRay, Inc.